Trial watch: Toll-like receptor ligands in cancer therapy.

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-01-01 DOI:10.1080/2162402X.2023.2180237

Julie Le Naour, Guido Kroemer

引用次数: 4

Abstract

Accumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological applications. Additionally, these immunotherapeutics have been extensively investigated over the past few years. Multiple clinical trials are currently evaluating the combination of TLR agonists with chemotherapy, radiotherapy, or different immunotherapies. Moreover, antibodies targeting tumor-enriched surface proteins that have been conjugated to TLR agonists are being developed to stimulate anticancer immune responses specifically within the tumor microenvironment. Solid preclinical and translational results support the favorable immune-activating effects of TLR agonists. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for anticancer immunotherapy.

查看原文本刊更多论文

试验观察:toll样受体配体在癌症治疗中的应用。

越来越多的证据表明toll样受体(TLR)激动剂作为免疫佐剂能有效地(重新)加强癌症免疫监测。到目前为止，三种TLR激动剂已被监管机构批准用于肿瘤学应用。此外，这些免疫疗法在过去几年中已被广泛研究。多项临床试验目前正在评估TLR激动剂与化疗、放疗或不同免疫疗法的联合使用。此外，针对已与TLR激动剂结合的肿瘤富集表面蛋白的抗体正在开发中，以在肿瘤微环境中特异性地刺激抗癌免疫反应。坚实的临床前和转化结果支持TLR激动剂有利的免疫激活作用。在这里，我们总结了TLR激动剂用于抗癌免疫治疗的临床前和临床进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.